The study did meet the primary PFS primary end point; the median PFS for dato-DXd is 6.9 months vs 4.9 months in the ...
DXD Capital Managing Director Chris Bailey discusses his company's latest survey results on the lending sentiment in the self ...
Trastuzumab deruxtecan (T-DXd) was effective in patients with HER2-positive (HER2+) metastatic breast cancer, with no new safety profiles observed. According to research presented at the European ...
The FDA has granted priority review to the supplemental biologics license application (sBLA) of fam-trastuzumab ...
Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed. Patients with hormone ...
R-DXd has previously shown promising clinical results in platinum-resistant ovarian, peritoneal, and fallopian tube cancers.
At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial highlighted a potential shift in frontline treatment for metastatic ...
New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering ...
The FDA granted breakthrough therapy designation to R-DXd for adults with CDH6-expressing platinum-resistant ovarian, peritoneal or fallopian tube cancers.
Patients with advanced squamous or nonsquamous NSCLC without a common EGFR-activating mutation whose disease had progressed on previous therapies including platinum-based chemotherapy, immune ...
Patient undergoing chemotherapy. Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.
High school and anime are like two peas in a pod — so it was no surprise to see High School DxD take off. Based on the light novel series of the same name by Ichiei Ishibumi, this supernatural comedy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback